P2Y12 receptor inhibitors: an evolution in drug design to prevent arterial thrombosisDanny KupkaDirk Sibbing
Oral P2Y12 inhibitors (P2Y12-I) are commonly used antiplatelet drugs in patients with end-stage kidney disease (ESKD) on chronic dialysis. Although gaps in prescription refills are quite common in patients with ESKD, it remains unclear whether P2Y12-I prescription refill patterns are associated wi...
P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? Dual antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor represents the cornerstone therapy for patients with acute coronary syndromes or unde... AD Oprea,WM Popescu - 《Cardiology Research & Practice》...
percutaneous coronary interventionplatelet aggregation inhibitorsdrug-eluting stentsIntroduction/ObjectivesMorita, FernandoWajngarten, MauricioKatz, MarceloFernandes-Silva, Miguel MoritaCaixeta, AdrianoFranken, MarceloLemos, Pedro A.Pesaro, Antonio E.Hosp Israelita Albert Einstein Dept Cardiol Sao Paulo Brazil...
Delle-Karth, "Clinical implications of drug-drug inter- actions with P2Y12 receptor inhibitors," Journal of Thrombosis and Haemostasis, vol. 12, no. 1, pp. 2-13, 2014.Siller-Matula JM, Trenk D, Krahenbuhl S, Michelson AD, Delle-Karth G, Clinical implications of drug-drug interactions ...
JACC Cardiovasc Interv, 10(2): 130-132Rollini, F., Franchi, F., and Angiolillo, D. J. (2017). Drug-drug interactions when switching between intravenous and oral P2Y12 receptor inhibitors: how real is it? JACC Cardiovasc. Interv. 10, 130-132. doi: 10.1016/j.jcin.2016.11.021...
All SectionsClinical Medicine, Cell, and Organism PhysiologyDisease BiomarkerEpidemiologyEpigenetic TherapyEvidence Based MedicineLife Stage Specific Medicine (LSSM)Mechanisms of DiseasesMethodology, Drug and Device DiscoveryMolecular Targeted TherapyOmics/InformaticsPersonalized Critical CarePersonalized Therapy and Dr...
The current ESC guideline recommends the use of potent P2Y12 inhibitors, ticagrelor or prasugrel, over clopidogrel, which has response variability associated with genetic mutation and drug interactions. However, the clear recommendation regarding selection of P2Y12 inhibitors in CKD patients including thos...